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Abstract
Neutrophils isolated from patients with chronic bronchitis and emphysema have been shown to have enhanced responses
to formyl peptides when assessed in vitro compared to age, sex matched controls. It is currently unclear whether the observed
differences are due to a ‘priming’ effect by a second agent in vivo, or whether this is a primary difference in the neutrophils.
We have studied the effects of interleukin-8, which is thought to be one of the major pro-inflammatory cytokines in chronic
lung disease and granulocyte macrophage colony stimulating factor (GMCSF), in order to assess their effects on neutrophil
chemotaxis and connective tissue degradation. In addition, we have assessed the effect of preincubation of these agents with
neutrophils for 30 min followed by stimulation with F-Met-Leu-Phe (FMLP) to investigate any possible ‘priming’ effect that
may be relevant to our clinical data. We report suppression of neutrophil chemotaxis to FMLP following incubation of the
neutrophils with both IL-8 and GMCSF. However, we have observed an additive effect of IL-8 and FMLP for neutrophil
degranulation leading to fibronectin degradation. The results suggest that IL-8 does not ‘prime’ neutrophils for subsequent
FMLP stimulation as observed in vivo. Although the results for GMCSF were similar for the chemotactic response, the agent
also had a synergistic effect on connective tissue degradation. However, it is concluded that neither agent could explain the
enhanced neutrophil responses seen in our patients. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Neutrophils (PMN) play a key role in pulmonary
defence, but have been implicated as a major cause
of tissue destruction leading to the development and
progression of chronic lung diseases [1]. It is thought
that persistent and/or excessive recruitment of PMN
to the airway followed by degranulation can also, in
some instances, lead to ampli¢cation and perpetua-
tion of the in£ammatory process, resulting in chronic
lung damage [2]. Studies in patients with chronic
bronchitis and emphysema have indicated that
PMN show an increased chemotactic response to a
standard chemoattractant together with increased
connective tissue degradation and upregulation by
F-Met-Leu-Phe (FMLP), compared to age and
smoking matched controls [3] and that these e¡ects
relate to increased receptor expression [4]. The impli-
cation of these observations is that in patients with
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chronic lung diseases, the PMN would show an en-
hanced chemotactic response leading to increased re-
cruitment to the lung and this, together with the
greater potential for connective tissue degradation,
could play a key role in the development and pro-
gression of the disease.
However, the reasons for the increased chemotac-
tic response and destructive potential of the PMN
from patients with COPD is largely unknown. Pre-
vious studies were carried out using the formyl pep-
tide FMLP as the stimulating agent. Whereas this
observation may relate to a primary di¡erence in
the neutrophils, it is possible that the PMN had
been primed for their response to FMLP and that
other mediators may play a key role in vivo. For
instance, endotoxin has been shown to prime PMN
for superoxide release in response to FMLP [5].
Another possible activating factor is interleukin-8
(IL-8) which is an important in£ammatory mediator
and may play a role in the pathogenesis of several
lung diseases through its chemotactic activity for
PMN [6]. In addition, IL-8 increases FMLP receptor
numbers [7] which would be consistent with our clin-
ical ¢ndings [4]. However, there is uncertainty con-
cerning the potential of IL-8 to stimulate other PMN
functions, including degradation of connective tissue
and superoxide production. Some investigators dem-
onstrated that IL-8 was unable to [7,8] or only
weakly able to [9] stimulate superoxide production
by PMN on its own. On the other hand, studies
have shown that IL-8 enhances the response of other
stimulants of superoxide production by PMN [7,8],
although this e¡ect was not con¢rmed by others [10].
There is also controversy regarding whether IL-8 has
an e¡ect on PMN degranulation with some studies
failing to demonstrate an e¡ect [11], while others
succeeded [12]. Furthermore, it is degranulation of
the primary granules that relate to connective tissue
degradation by the release of proteases and this has
yet to be studied.
The experiments reported here were performed to
attempt to clarify some of these controversies. In
particular, we wished to determine if IL-8 is able to
prime PMN in a way which might explain the in-
creased functional responses that were seen for
PMN from patients with chronic destructive lung
diseases. Finally, we wished to clarify whether IL-8
does a¡ect these PMN functions alone. Additional
studies were carried out with granulocyte macro-
phage colony stimulating factor (GMCSF) in a sim-
ilar way, since this agent can also increase the num-
ber and a⁄nity of FMLP receptors [13] which would
be consistent with our ¢nding in patients [4].
2. Materials and methods
2.1. Isolation of peripheral blood neutrophils
Venous blood was collected from normal healthy
subjects into lithium heparin tubes and PMN iso-
lated using the method of Jepson and Skottun [14].
Each sample was diluted with an equal volume of
0.15 M sodium chloride and layered onto a Percoll
gradient (Sigma, Dorset, UK). The top layer con-
sisted of 2 ml of 54% Percoll (density 1.075 g/ml)
and the lower layer 3 ml of 78% Percoll (density
1.096 g/ml). The gradients were then centrifuged at
200Ug for 25 min at room temperature. The PMN
s 96% pure and s 98% viable (by exclusion of Try-
pan blue) were harvested from the interface between
the 54 and 78% Percoll layers, washed twice in 0.15
M sodium chloride, counted and resuspended in the
appropriate assay medium; RPMI 1640 (Flow Lab-
oratories, Richmansworth, UK) for the ¢bronectin
degradation assay or RPMI solution containing
2 mg/ml bovine serum albumin for the chemotaxis
assay. All reagents were con¢rmed to contain less
than 20 ng/l of endotoxin activity using the KabiVi-
trum Coat Test (Flow Laboratories, Richmansworth,
UK).
2.2. PMN chemotaxis
The PMN chemotaxis assay was based on the
method described by Falk et al. [15], using the 48-
well microchemotaxis chamber. The chemotaxis
chamber was assembled by pipetting 27 Wl of the
chemoattractants in the lower wells, a 2 Wm pore
polyvinylpyrolidone (PVP)-free polycarbonate ¢lter
(Costar Nucleotide, Costar UK, High Wycombe,
UK) was then carefully placed over the lower wells
followed by a rubber gasket and the upper half of the
chamber secured with screws. The PMN (50 Wl sus-
pended at 1.5U106 cells/ml of assay medium) were
then carefully pipetted into the upper wells and the
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chemotaxis chamber incubated at 37‡C for 20 min.
The chamber was then disassembled and the ¢lter
removed, wiped across a wiper blade (to remove
any cells that had not migrated through the pores)
and ¢xed and stained using Di¡-quick (Baxter, UK).
The cells which had migrated through the 2 Wm pores
to the lower surface of the membranes were counted
at U400 magni¢cation (¢ve random ¢elds per well).
A mean value was obtained for each well and the
average value for 3 replicate wells was taken as the
result for that sample.
2.3. Experimental design
Firstly, PMN chemotaxis to a range of IL-8 (RpD
Systems, Abingdon, Oxon) concentrations (0.01^100
nM) was performed to establish the dose response
curve of PMN chemotaxis to IL-8. Once the dose
response had been established, the e¡ect of IL-8 on
PMN chemotaxis to FMLP was investigated. This
was carried out using two di¡erent concentrations
of IL-8, ¢rstly a non-chemotactic ‘low dose’ and sec-
ondly the optimal concentration for PMN chemo-
taxis (0.1 and 5 nM, respectively). The PMN were
incubated with the IL-8 (0.1 and 5 nM) for 30 min at
37‡C followed by washing twice with 0.15 M sodium
chloride. The washed cells were then recounted and
suspended in assay medium for the assessment of
chemotaxis to FMLP at 0.1, 1, 10 and 100 nM.
Secondly, PMN chemotaxis to combinations of
IL-8 and FMLP was investigated using non-chemo-
tactic and optimal concentrations of both agents, i.e.
low dose of both IL-8 and FMLP (0.1 and 0.2 nM,
respectively), optimal concentrations of IL-8 and
FMLP (5 and 10 nM, respectively), low dose IL-8
(0.1 nM) with an optimal FMLP concentration (10
nM) or lastly, optimal IL-8 (5 nM) with low dose
FMLP (0.2 nM),
2.4. Fibronectin degradation
Degradation of ¢bronectin (FN) by PMN is due to
the release of proteinases by degranulation of the
primary granules and was assessed using the method
of Campbell et al. [16] as modi¢ed by Burnett et al.
[3]. Brie£y, puri¢ed human FN (Sigma, Dorset, UK)
was iodinated by the chloramine-T method with so-
dium 125iodine (ICN Flow, High Wycombe, UK).
The radiolabelled FN was diluted with unlabelled
FN in 0.05 M carbonate/bicarbonate bu¡er (pH
9.6) to give 2000 cpm/Wg FN and then dispensed
into the wells of microtitre plates as 30 Wg FN/well
in 200 Wl bu¡er. The plates were allowed to dry at
37‡C and then washed three times with phosphate
bu¡ered saline (pH 7.2) to remove any unbound io-
dine.
Fig. 1. (a) The concentration e¡ect of IL-8 on PMN chemo-
taxis. The data histograms are mean þ S.E. of seven experi-
ments. (b) E¡ect of IL-8 preincubation at the concentrations of
0.1 nM (a) and 5 nM (F) on FMLP dose response for chemo-
taxis in comparison with control (E). The data are shown as
mean þ S.E. of ¢ve experiments. A signi¢cant (*P6 0.04) sup-
pression of FMLP stimulated PMN chemotaxis is seen after
preincubation with IL-8 which was greater in the presence of
5 nM compared to 0.1 nM (P6 0.04).
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Freshly puri¢ed PMN suspended in RPMI me-
dium (3U106 cells/ml) were preincubated with IL-8
at increasing concentrations (0.01^100 nM) for 30
min at 37‡C as might be expected since it is likely
that PMN within the pulmonary vasculature, extrac-
ellular £uid and lung secretions would be exposed to
varying concentrations of IL-8 in vivo persistently
rather than transiently. Following the preincubation,
200 Wl of the cells with varying concentrations of IL-
8 were dispensed into the wells of the microtitre plate
coated with FN and the plate incubated in a humidi-
¢ed atmosphere of 5% CO2/95% air for 3 h at 37‡C.
After 3 h incubation the supernatant was collected
from the wells and the amount of FN degraded was
assessed by counting the release of 125I using an LKB
Multigamma counter. The 125I counts in the wells
containing RPMI alone (blank wells) were deducted
from the results for those wells containing PMN. The
result for each assay was determined from the mean
value for three replicate wells. In order to assess the
e¡ects of IL-8 alone and IL-8 in addition to FMLP
(as more than one stimulating agent may be found in
lung secretions), the experiments were performed
with cells in the absence of IL-8 (control, resting
cells), with cells preincubated with increasing concen-
trations of IL-8 with and without optimal concentra-
tions of FMLP (1 WM) and with cells stimulated with
FMLP, but without IL-8.
2.5. E¡ect of GMCSF
Studies were also performed to assess the e¡ect of
GMCSF on PMN chemotaxis and degradation of
FN. Firstly, GMCSF (RpD Systems, Abingdon,
Oxon) was con¢rmed to be non-chemotactic for
PMN at concentrations up to 10 nM. Increasing
concentrations of GMCSF were preincubated with
PMN for 30 min at 37‡C in order to assess the e¡ect
of this agent on PMN chemotaxis to the optimal
concentration of FMLP (n = 4).
Secondly, the e¡ect of GMCSF on PMN degrada-
tion of FN was assessed by preincubating PMN with
increasing concentrations of GMCSF (0.001^10 nM)
for 30 min at 37‡C before performing the assay. Fi-
nally the e¡ect of GMCSF preincubation, followed by
subsequent stimulation with varying concentrations
of FMLP, on PMN mediated degradation of FN
was assessed using cells preincubated with GMCSF
concentrations of 0.01 or 1 nM prior to performing
the assay to determine whether this cytokine was
able to prime neutrophils for these responses.
2.6. Data analysis
Statistical analyses of the e¡ects of IL-8 on PMN
chemotaxis and FN degradation with or without
FMLP stimulation were performed using Wilcoxon
signed rank test for paired data.
3. Results
3.1. PMN chemotaxis
The e¡ect of IL-8 on PMN chemotaxis is shown in
Fig. 1a, indicating a dose related response for PMN
chemotaxis with a maximum e¡ect at a concentration
of 5 nM (23.6; S.E. þ 1.4 cells/HPF). When PMN
chemotaxis to FMLP was measured after preincuba-
tion with a non chemotactic ‘low’ dose (0.1 nM) or
an optimal dose (5 nM) of IL-8, a signi¢cant
(P6 0.04) suppression was seen from a maximal con-
trol mean value of 32.5 þ 3.2 for 10 nM FMLP to
26.8 þ 2.9 cells/HPF in the presence of 0.1 nM IL-8
Table 1
Neutrophil chemotaxis to combinations of IL-8 and FMLP
Control IL-8 concentrations
Low (0.1 nM) Optimal (5 nM)
Control 2.1 (0.4) 17.1 (1.1)
FMLP concentration low dose 0.2 nM 1.1 (0.4) 2.9 (0.6) 20.6 (2.9)
Optimal 10 nM 25.0 (2.6) 27.8 (2.8) 30.2 ( þ 2.6)*
Values are means (n = 5). Standard errors are shown in parentheses. The only combination showing a greater e¡ect than a single agent
alone is seen with optimal concentrations of each chemoattractant.
*P6 0.04.
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and this was greater (P6 0.04) in the presence of
5 nM IL-8 (18.2 þ 3.2 cells/HPF). These results are
summarised in Fig. 1b.
In the second series of experiments, non-chemo-
tactic (low dose) and ‘optimal concentrations’ of
FMLP and IL-8 were mixed together in each combi-
nation and the PMN chemotactic response was as-
sessed. When low doses of IL-8 (0.1 nM) and FMLP
(0.2 nM) were used together as the chemoattractant,
the PMN chemotactic response was only 2.9 þ 0.6
cells/HPF, which was similar to the result of both
agents separately.
Fig. 2. (a) The e¡ect of increasing concentrations of IL-8 on degradation of ¢bronectin (FN) by PMN. The data histograms are
mean þ S.E. of 6 experiments. (b) The e¡ect of increasing concentrations of IL-8 on degradation of ¢bronectin (FN) by PMN stimu-
lated with 1 Wm FMLP. The data histograms and mean þ S.E. of ¢ve experiments.
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When optimal and low doses of IL-8 or FMLP
were mixed the results showed a small increase in
chemotactic response compared to each agent alone,
although this was not statistically signi¢cant How-
ever the combination of optimal concentrations of
IL-8 (5 nM) and FMLP (10 nM), although demon-
strating a greater chemotactic response (30.2 þ 2.6
cells/HPF; P6 0.04) was lower than would be ex-
pected for an additive e¡ect (v48 cells/HPF). These
results are summarised in Table 1.
3.2. Fibronectin degradation by PMN
Fibronectin degradation by PMN was increased
slightly, but signi¢cantly, (P6 0.02) by IL-8 with a
maximal e¡ect at 10 nM as shown in Fig. 2a (from a
control mean of 1.93 þ 0.31 Wg FN to 2.85 þ 0.33).
Fibronectin degradation by PMN stimulated with
1 WM FMLP (Fig. 2b) was also increased (P6 0.04)
after preincubation of the cells with IL-8 in a dose
dependent manner from a control value of
4.67 þ 0.61 to 6.20 þ 0.77 at 10 nM IL-8, although
no change was seen at concentrations of IL-8 that
had no e¡ect alone (n = 6).
The average increase in ¢bronectin degradation by
IL-8 alone (0.92 Wg) appeared less than the increase
induced in the presence of FMLP (1.53 Wg). How-
ever, this failed to reach statistical signi¢cance. In
view of this, the experiment was repeated with a
further series of neutrophils (n = 6), comparing the
e¡ect of 10 nM IL-8 in the presence and absence
of 1 WM FMLP. Again, the increase from control
due to IL-8 alone (0.45 þ 0.03 Wg) was not statisti-
cally di¡erent to that seen in the presence of FMLP
compared to FMLP alone (0.85 þ 0.45 Wg), suggest-
ing the e¡ect of the two agents is no more than
additive, rather than demonstrating a synergistic ef-
fect.
3.3. Response to GMCSF
GMCSF itself was not chemotactic in the concen-
trations used. However, preincubation of PMN with
increasing concentrations of GMCSF resulted in a
dose related reduction in the chemotactic response
of the PMN to 10 nM FMLP from a control value
of 28.9 cells/HPF, S.E. þ 1.7 to 14.8 þ 0.38 with 10
nM GMCSF (Fig. 3).
On the other hand, GMCSF alone did produce an
increase in ¢bronectin degradation at concentrations
of 0.1 nM and above (control, 3.41 þ 0.85; 0.01 nM,
3.39 þ 0.76; 0.1 nM, 4.28 þ 1.0; 10 nM, 4.65 þ 0.88).
Following preincubation of PMN with a non-e¡ec-
Fig. 3. The e¡ect of increasing concentrations of GMCSF on
chemotactic response of neutrophils to 10 nM FMLP is shown.
Histograms are mean þ S.E. (n = 4).
Fig. 4. The e¡ect of 0.1 nM GMCSF on the degradation of ¢-
bronectin by FMLP. Open histograms are control (FMLP
alone) þ S.E.
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tive concentration of GMCSF (0.01 nM) the subse-
quent response to FMLP showed no increase (1 WM
FMLP, 6.68 þ 0.3; FMLP+GMCSF, 6.51 þ 0.4).
However in the presence of 0.1 nM GMCSF which
had a small e¡ect on ¢bronectin degradation (con-
trol, 3.41 þ 0.85; 0.1 nM GMCSF, 4.28 þ 1.0), the
response to FMLP was enhanced (see Fig. 4).
4. Discussion
PMN are considered as major cellular components
in the defence of the lung against bacteria and fungal
infection [17]. Although PMN chemotaxis, degranu-
lation (leading to proteinase release) and superoxide
anion production all play important roles in host
defence, excessive and/or prolonged action would
lead to increased tissue injury typical of chronic de-
structive lung diseases [1,2]. Previous studies have
shown that PMN obtained from patients with
chronic lung diseases show an increased chemotactic
response and connective tissue degradation in re-
sponse to FMLP, compared to age and smoking
matched controls [3] and this was associated with
increased FMLP receptor expression [4]. However,
it was not certain whether this represented a primary
di¡erence in cell responses and hence was central to
the pathogenesis of disease, or a secondary phenom-
enon due to cell activation or ‘priming’ as a result of
established lung disease. The term ‘priming’ is used
to describe the phenomenon that a non-e¡ective dose
of one agent alone enhances an e¡ect of another
when assessing PMN function. However, when the
two agents interact at e¡ective doses they may be
‘additive’ (the increase is greater than that expected
for either agent individually) or ‘synergistic’ when the
combined e¡ect exceeds the additive response ex-
pected for both agents. The current study was carried
out as part of a series of experiments to explore the
possibility that partial activation or ‘priming’ of neu-
trophils in patients with lung disease due to exposure
to a second agent in vivo was responsible for the
enhanced responses noted previously [3].
There are a variety of stimulatory molecules for
PMN that may originate in the lung of patients
with chronic obstructive lung diseases [18^21].
Among them, IL-8 is thought to be a major cytokine
responsible for PMN recruitment [19]. Not only pul-
monary macrophages and epithelial cells, but also
the PMN itself might be important as sources of
IL-8. However, although it is known that IL-8 is a
major chemoattractant and can increase mobilisation
and expression of FMLP receptors [7], it is uncertain
whether it can increase other PMN functions, either
alone or in conjunction with other cytokines. We
performed the current study to determine whether
IL-8 can enhance PMN functions with an appropri-
ate experimental design to determine whether IL-8
could have been responsible for the increased re-
sponse of PMN in patients with lung disease [3].
Results reported here con¢rm that IL-8 acts as a
major chemoattractant. Studies using the Boyden
chamber indicate the typical dose response with no
directed cell migration occurring at concentrations of
10 pM or less. Thereafter, chemotaxis increases
reaching a maximum at 5 nM followed by a decrease
in directed cell movement at greater concentrations.
This overall pattern of response is very similar to
that seen for other standard chemoattractants and
the decrease in directed cell movement at high con-
centrations is the result of excessive neutrophil acti-
vation and spreading associated with random motion
above the chemotaxis membrane, thereby decreasing
directed migration through the membrane.
This activation at higher concentration is con-
¢rmed by assessment of other neutrophil functions.
Fibronectin degradation by neutrophils is predom-
inantly the result of release of neutrophil elastase
due to degranulation of the primary granules [22].
Studies with IL-8 con¢rm that this cytokine had a
positive action on connective tissue degradation by
neutrophils, although no e¡ect is seen until the con-
centration reached 1 nM. The maximum e¡ect at
10 nM led to a modest increase (48% compared to
143% for 1036 M FMLP) con¢rming the studies of
previous workers [11]. This result indicates that neu-
trophil activation as assessed by this method occurs
at concentrations above 1 nM and would therefore
be consistent with a reduction in the chemotactic
response seen at high concentrations as discussed
above.
Whether these observations of the e¡ect of IL-8
can explain our previous ¢ndings with neutrophils
from patients with chronic bronchitis and emphyse-
ma [3] seems less certain. In that study, unstimulated
neutrophils from the patients with emphysema
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showed a 170% increase in degranulation as assessed
by ¢bronectin degradation compared to age and
smoking matched controls. Furthermore, stimulation
with FMLP led to a further increase (189%) in ¢bro-
nectin degradation and this value remained 130%
greater than control.
From the studies described here, although IL-8
alone produced an increase in ¢bronectin degrada-
tion by resting neutrophils there was no suggestion
of ‘priming’ of the neutrophils with this chemokine
since the increase in ¢bronectin degradation by
FMLP was unaltered by the presence of IL-8 at con-
centrations below which IL-8 had its own e¡ect. In
addition, the increase in ¢bronectin degradation in
the presence of both IL-8 and FMLP was only addi-
tive and less than that observed in our previous clin-
ical study. The implications of these ¢ndings are that
although IL-8 itself can have a modest ‘additive’ ef-
fect on ¢bronectin degradation, the data do not ex-
plain our previous ¢ndings in bronchitis and emphy-
sema. Previous studies in vitro have, however, shown
a priming e¡ect for elastase release from PMN with
TNFK, PAF and IL-1L when PMN are subsequently
stimulated with IL-8 and/or FMLP [23,24].
Of most importance is the observations on the
chemotactic response. In our previous studies, neu-
trophils from patients with chronic bronchitis and
emphysema showed enhanced chemotaxis to FMLP
compared to neutrophils from patients with other
in£ammatory lung diseases and those from age and
smoking matched controls [3]. Although the current
studies con¢rm that IL-8 is a major chemoattractant
and when preincubated with FMLP leads to an in-
creased chemotactic response than to either agent
alone, the opposite e¡ect was seen when IL-8 was
mixed with neutrophils. The experiments were per-
formed in this way on the assumption that any IL-8
being released from the lung in patients with estab-
lished lung disease would be in contact with the cir-
culating neutrophils for a prolonged period of time
prior to them being harvested and tested in the chem-
otactic assay described by us previously [3]. The ex-
act mechanism for the reduction caused by IL-8 is
uncertain, but may relate to the neutrophils being
presented with two independent signals from each
section of the chemotactic chamber. For instance, it
is known that chemotactic response to chemoattrac-
tants, such as IL-8, FMLP and LTB4, is reduced by
placing the neutrophils in the chemoattractant during
checkerboard experiments since this reduces the
chemotactic gradient. Thus, although the cells were
washed, receptor binding by IL-8 would activate the
cells and thus in£uence cell migration in this assay
compared to control cells. This phenomenon has
been observed in cystic ¢brosis where decreased
chemotaxis of circulating neutrophils was thought
to re£ect previous exposure to chemoattractants
[20]. Thus, this form of priming/activation would
give the opposite e¡ect to that seen in vivo in our
previous study in emphysema [3].
In a subsequent study, we have demonstrated that
neutrophils from patients with chronic bronchitis
and emphysema had increased numbers of FMLP
receptors expressed on the surface of the cell [4].
The number of receptors was related to the chemo-
tactic response and hence this was thought to explain
the mechanism of increased chemotaxis. Although
previous published work has indicated that the
priming e¡ect certainly with IL-1L is not associated
with increased receptor expression, we decided to
study a cytokine which would since this should be
more relevant to our in vivo data. Thus, we inves-
tigated the e¡ect of preincubating neutrophils with
low concentrations of GMCSF that has been shown
to increase surface expression of FMLP receptors
[22], which re£ects activation of neutrophils and de-
granulation of the speci¢c granules. Our results show
that although this cytokine is not chemotactic the
overall e¡ect was to reduce the chemotactic response
to FMLP. Subsequent experiments (data not shown)
indicated that incubation of neutrophils with
GMCSF resulted in the release of IL-8 into the neu-
trophil supernatant (consistent with previously pub-
lished data [25]) and the supernatant was con¢rmed
to be chemotactic. This would therefore have a sim-
ilar e¡ect to a checkerboard experiment by e¡ectively
exposing the neutrophils to a chemoattractant in the
upper chamber and providing a reverse or reduced
chemotactic gradient, thereby decreasing migration
to the lower side of the membrane in the Boyden
chamber assay. Thus, the e¡ects of GMCSF may
be indirect and related to the IL-8 e¡ect discussed
above. On the other hand, GMCSF had a synergistic
e¡ect on ¢bronectin degradation by PMN in re-
sponse to FMLP. Thus, although the GMCSF e¡ect
could explain our previous results in patients for ¢-
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bronectin degradation, it would not explain the che-
motactic results.
Overall, although the current study has con¢rmed
that IL-8 and GMCSF activate some neutrophil
functions and act additively or synergistically (re-
spectively) with FMLP in ¢bronectin degradation,
this activation process decreases chemotactic re-
sponse as studied here. Thus, the experiments with
IL-8 and GMCSF could not explain our previous
¢ndings of increased chemotactic and connective tis-
sue degradation responses in patients with chronic
bronchitis and emphysema. We have not investigated
the e¡ects of other cytokines (IL-1L, TNFK and
PAF) which have previously been shown to have
priming e¡ects for PMN elastase release and super-
oxide production [23,24] and could also have priming
e¡ects for PMN chemotaxis. The previously reported
data would not, however, be able to explain the in-
crease in FMLP receptor numbers seen in our patient
group [4]. This suggests that if the phenomenon is
caused by the presence of lung disease, it is likely to
be a mechanism that increases FMLP receptor ex-
pression on the cell surface without activation of
the neutrophils. Alternatively, as suggested previ-
ously [4], the increased FMLP receptor expression
may be a primary event and, therefore, central to
the pathogenesis of disease.
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